DNB Fund-Biotechnology Retail A EUR

Reference Data

ISIN LU2814038266
Valor Number 134925902
Bloomberg Global ID
Fund Name DNB Fund-Biotechnology Retail A EUR
Fund Provider DNB Asset Management AS Stockholm, Sweden
Phone: +46 8 473 41 00
Web: www.cim.se
Fund Provider DNB Asset Management AS
Representative in Switzerland FundPartner Solutions (Suisse) SA
Genève 75
Distributor(s)
Asset Class Other Funds
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund does not charge any issuing commission and/or fees (units are issued at the NAV)
Redemption Condition The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV)
Investment Strategy *** The Sub-Fund seeks to invest mainly in equities of companies operating in or associated with the biotechnology, diagnostics, pharmaceuticals, biomedicine, gene therapy and other health care related industries, with the aim to achieve a positive relative return over the long- term. Geographically the Sub-Fund has full flexibility.
Peculiarities

Fund Prices

Current Price * 107.32 EUR 16.01.2025
Previous Price * 108.21 EUR 15.01.2025
52 Week High * 113.78 EUR 11.11.2024
52 Week Low * 103.62 EUR 03.10.2024
NAV * 107.32 EUR 16.01.2025
Issue Price * 107.32 EUR 16.01.2025
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 5,406,526
Unit/Share Assets *** 2,138,024
Trading Information SIX

Performance

YTD Performance +0.39% 31.12.2024
16.01.2025
YTD Performance (in CHF) +0.22% 31.12.2024
16.01.2025
1 month -2.12% 16.12.2024
16.01.2025
3 months -2.66% 16.10.2024
16.01.2025
6 months +0.13% 19.07.2024
16.01.2025
1 year - -
2 years - -
3 years - -
5 years - -

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

argenx SE 6.14%
Biomarin Pharmaceutical Inc 5.86%
Vertex Pharmaceuticals Inc 4.73%
Amgen Inc 4.66%
Intra-Cellular Therapies Inc 3.66%
Neurocrine Biosciences Inc 3.62%
Xenon Pharmaceuticals Inc 3.21%
Exact Sciences Corp 3.17%
Regeneron Pharmaceuticals Inc 3.06%
Alnylam Pharmaceuticals Inc 3.00%
Last data update 30.11.2024

Cost / Risk

TER *** 1.56%
TER date *** 30.06.2024
Performance Fee *** 10.00%
PTR
Max. Management Fee *** 1.75%
Ongoing Charges ***
SRRI ***
SRRI date *** 31.12.2024

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 ***
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 ***

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)